N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge — 97 Percentage of Participants
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
N/A N=214 Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques
Stable Angina
Primary: Percentage of Participants With Major Adverse Cardiac Events(MACE) — 1.72; 6.86 percentage of participants
N/A N=100 NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Atherosclerosis · Coronary Artery Disease
Primary: Technical Success Rate — 99.2 percentage of lesions
N/A N=82 TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
Peripheral Arterial Disease
Primary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants
Phase 3 N=100 Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure — 16.9 Percentage of…
N/A N=30 Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: MLD SB Diameter — 08.; 1.0; 2.3; 2.2 mm
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
N/A N=8,476 Factors Contribute to Very Late Stent Thrombosis After New Generation DES Implantation in China
Stent Thrombosis
Primary: Very Late Stent Thrombosis — 92; 35 Participants
N/A N=241 Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.
Coronary Artery Disease
Primary: In-segment Percent Diameter Stenosis at 8 Months Post-procedure — 37.4 percent diameter stenosis — p=<0.001
N/A N=65 RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
Arterial Occlusive Diseases · Myocardial Ischemia · Cardiovascular Diseases
Primary: Target Lesion Failure(TLF) — 4.62 percentage of TLF
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
N/A N=60 Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Coronary Artery Disease · Atherosclerosis
Primary: Minimum Stent Area After Percutaneous Coronary Intervention — 6.7; 6.9 mm^2
Phase 4 N=597 Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
N/A N=299 SuperNOVA Clinical Stenting Trial
Atherosclerosis of Native Arteries of the Extremities, Unspecified
Primary: Primary Safety Endpoint and Components — 85.8; 14.2; 0.0; 0.4 percentage of participants
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Phase 2 N=41 PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
Phase 4 N=479 Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Myocardial Infarction
Primary: Device-oriented Composite Outcome — 12; 13 participants
N/A N=60 Bare Metal Bifurcation Stent Clinical Trial in Humans
Coronary Artery Disease · Myocardial Ischemia
Primary: Number of Participants With Target Vessel Failure (TVF) at 30 Days Post Procedure. — 2 Participants
N/A N=1,334 Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Coronary Artery Disease · Atherosclerosis, Coronary · Myocardial Ischemia
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation — 6.32; 8.90 Percentage of participants
N/A N=8 Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement
Coronary Artery Disease
Primary: Percent Stent Coverage — 1; 0; 3; 1 Participants
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
Phase 3 N=102 The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 3.2 percentage of participants — p=<0.0001
N/A N=499 STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Peripheral Arterial Disease
Primary: Percentage of Participants With Freedom From Device and Procedure-related Death and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion…
N/A N=15 Coronary Flow Reserve Following Orbital Atherectomy
Coronary Artery Disease
Primary: Coronary Flow Reserve (CFR) — 2.23 Ratio